Publication date context: February 11, 2026. A prospective noninterventional study is evaluating a perioral rejuvenation procedure using Saypha Rich and Saypha Filler Lidocaine. The study seeks real world data on safety and performance while maintaining standard clinical practice. Not yet recruiting is noted for the trial at this time. Sponsors listed are Yuvell and Croma-Pharma GmbH. The trial is registered on ClinicalTrials.gov under NCT07398768. Clinicians and device sponsor teams may watch this record for future updates.
The following overview explains what changed in this area, who is affected and why it matters for regulatory strategy. The source text indicates that perioral wrinkles, crow’s feet, lip volume enhancement and lip aging are among the conditions addressed by the study and that the interventions involve two Saypha devices. This signals a focus on combination device use to achieve cosmetic outcomes in facial regions where improve quality of life is a potential driver for patients and clinicians alike.
What changed in perioral rejuvenation research and regulation?
The record describes a real world evidence approach that aims to observe outcomes in routine care rather than in a randomized trial setting. This design aligns with regulatory expectations for post market safety and effectiveness data while avoiding procedural shifts in standard practice.
Key clinical targets include perioral wrinkles, crow’s feet, lip volume enhancement and lip aging. The interventions listed are two Saypha devices, Saypha Rich and Saypha Filler Lidocaine. The use of Lidocaine as part of the filler device aims to improve patient comfort during treatment. The not yet recruiting status indicates that results will come as the study progresses rather than from immediate trial completion.
Who is affected by this study and its regulatory implications?
Stakeholders include the device sponsor, Croma-Pharma GmbH, and the study sponsor Yuvell, along with clinical investigators who will implement the procedures in real world settings. Regulatory teams in medical device companies should monitor such prospective noninterventional activity for signals that could inform labeling, risk management and post market surveillance strategies.
Patients seeking perioral rejuvenation and clinicians performing cosmetic facial procedures may benefit from clearer safety data and performance signals once the study results are published. Because this work is registered in a public repository, regulators and industry observers can track progress and ensure alignment with applicable MDR requirements and national guidelines.
What is being studied and how will outcomes be measured?
The design is prospective and noninterventional. It plans to observe outcomes in routine use of Saypha Rich and Saypha Filler Lidocaine for conditions around the mouth and lips. Specific endpoints and statistical methods are not detailed in the public record, which is typical for informing purposes until the study progresses. Safety signals, device performance and consumer satisfaction are common data types in such work and will likely inform future regulatory submissions or labeling discussions.
Which devices are involved and what is their regulatory status?
The devices are Saypha Rich and Saypha Filler Lidocaine both produced by Croma-Pharma GmbH. The inclusion of Lidocaine suggests a focus on enhancing patient comfort during injection or placement, consistent with common clinical practice for dermal filler procedures. The public record does not provide a final regulatory classification decision or marketing status for the study itself, but the existence of a prospective design using these devices implies ongoing regulatory oversight consistent with MDR provisions on medical device studies and cosmetic applications.
External trial record: ClinicalTrials.gov NCT07398768.
What is the regulatory context for this trial?
Prospective noninterventional studies are part of real world evidence programs used by manufacturers to gather data on safety and performance in ordinary clinical settings. Under the guidelines of the medical device regulation framework, such activities must follow risk management, labeling and post market surveillance obligations. The manufacturer statements in the record reflect the expected use of the Saypha devices and the intended cosmetic outcomes as claimed by the sponsor.
The MDR and national regulators expect transparency in trial design, clear disclosure of sponsorship and potential conflicts, and robust data collection plans. Not yet recruiting status means the study has not yet begun patient enrollment. Stakeholders should monitor updates to understand when data will become available and how the results might influence labeling or post market obligations.
FAQ
- 1. What is the current recruitment status The record indicates not yet recruiting as of the posting date.
- 2. Which devices are used in the study Saypha Rich and Saypha Filler Lidocaine from Croma Pharma GmbH.
- 3. Where can the trial be found and tracked The study is listed on ClinicalTrials.gov under NCT07398768 external link provided above.
Conclusion and implications for practice
This prospective noninterventional study appears aimed at building real world evidence for perioral rejuvenation using Saypha devices. For clinicians the results may influence patient counseling around safety and expected cosmetic outcomes. For device sponsors the data could inform risk management and labeling strategies that align with MDR expectations. Regulators will monitor the study as part of broader post market evidence efforts. Readers should stay informed by checking the ClinicalTrials.gov record for updates.
Disclaimer: This article provides information for professionals and is not legal advice or a substitute for regulatory consultation.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07398768?term=medical+device